• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Dashboard
    Quantisnow Logo

    © 2025 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlerts
    Company
    AboutQuantisnow PlusContactJobs
    Legal
    Terms of usePrivacy policyCookie policy

    Mannatech Reports Third Quarter End 2023 Financial Results

    11/7/23 6:00:00 AM ET
    $MTEX
    Medicinal Chemicals and Botanical Products
    Health Care
    Get the next $MTEX alert in real time by email

    Mannatech, Incorporated (NASDAQ:MTEX), a global health and wellness company committed to transforming lives to make a better world, today announced financial results for its third quarter of 2023.

    Third Quarter End Results

    Third quarter net sales for 2023 were $32.6 million, a decrease of $2.9 million, or 8.3%, as compared to $35.5 million in the third quarter of 2022. Our net sales decreased 8.5% on a constant dollar basis (see Non-GAAP Measures, below) however, foreign exchange increased GAAP net sales by $0.1 million, mostly due to the strengthening of the Korean Won.

    Third quarter operating income for 2023 was $0.2 million as compared to operating income of $1.4 million for the third quarter of 2022.

    Net income was $18,000 or $0.01 per diluted share, for the third quarter of 2023, as compared to net income of $1.2 million, or $0.61 per diluted share, for the third quarter of 2022.

    For the three months ended September 30, 2023, overall selling and administrative expenses increased by $0.2 million to $6.9 million, as compared to $6.7 million for the same period in 2022. The increase in selling and administrative expenses consisted of a $0.2 million increase in marketing costs and a $0.1 million increase in warehouse costs, which was partially offset by a $0.1 million decrease in payroll costs.

    For the three months ended September 30, 2023, other operating costs increased by $0.1 million to $5.2 million, as compared to $5.1 million for the same period in 2022. The increase in operating costs was primarily due to a $0.3 million increase in bad debt, a $0.2 million increase in consulting fees for Trulu, a new venture to serve as our innovation hub, which was partially offset by a $0.2 million decrease in travel and entertainment, a $0.1 million decrease in office expenses and a $0.1 million decrease in credit card fees.

    The approximate number of new and continuing independent associate and preferred customer positions held by individuals in Mannatech's network and associated with purchases of products as of September 30, 2023 and 2022 were approximately 146,000 and 152,000, respectively. Recruitment of new independent associates and preferred customers increased by 20.9% to 23,296 in the third quarter of 2023 as compared to 19,273 in the third quarter of 2022.

    Year-to-date Third Quarter Results

    For the nine months ended September 30, 2023, net sales were $99.3 million, a decrease of $3.6 million, or 3.5%, as compared to $102.9 million for the same period in 2022. Our net sales declined 1.2% on a constant dollar basis (see Non-GAAP Measures, below) as foreign exchange decreased GAAP net sales by $2.4 million mostly due to the decline of the Korean Won, Japanese Yen and Australian Dollar.

    Operating loss for the nine months ended September 30, 2023 was $0.1 million as compared to operating income of $2.2 million for the same period in 2022.

    Net loss was $0.5 million, or $0.26 per diluted share, for the nine months ended September 30, 2023, as compared to net income of $2.0 million, or $1.01 per diluted share, for the same period in 2022.

    We did not pay a quarterly dividend for the second quarter, which preserved approximately $0.4 million of cash and we will not pay a quarterly dividend for this quarter, which will preserve an additional $0.4 million of cash.

    Non-GAAP Measures

    In addition to results presented in accordance with GAAP, this press release and related tables include certain non-GAAP financial measures, including a presentation of constant dollar measures. We disclose operating results that have been adjusted to exclude the impact of changes due to the translation of foreign currencies into U.S. dollars, including changes in: Net Sales, Gross Profit, and Income from Operations. We believe that these non-GAAP financial measures provide useful information to investors because they are an indicator of the strength and performance of ongoing business operations. The constant currency figures are financial measures used by management to provide investors an additional perspective on trends. Although we believe the non-GAAP financial measures enhance investors' understanding of our business and performance, these non-GAAP financial measures should not be considered an exclusive alternative to accompanying GAAP financial measures. Please see the accompanying table entitled "Non-GAAP Financial Measures" for a reconciliation of these non-GAAP financial measures.

    Safe Harbor statement

    This release contains "forward-looking statements" within the meaning of Section 27A of the Securities Act of 1933, as amended, Section 21E of the Securities Exchange Act of 1934, as amended, and the Private Securities Litigation Reform Act of 1995. These forward-looking statements generally can be identified by use of phrases or terminology such as "may," "will," "should," "hope," "could," "would," "expects," "plans," "intends," "anticipates," "believes," "estimates," "approximates," "predicts," "projects," "potential," and "continues" or other similar words or the negative of such terminology. Similarly, descriptions of Mannatech's objectives, strategies, plans, goals or targets contained herein are also considered forward-looking statements. Mannatech believes this release should be read in conjunction with all of its filings with the United States Securities and Exchange Commission and cautions its readers that these forward-looking statements are subject to certain events, risks, uncertainties, and other factors. Some of these factors include, among others, the impact of COVID-19 on Mannatech's business, the availability and effectiveness of vaccines on a widespread basis, the impact of any mutations of the COVID-19 virus, the current conflict between Russia and Ukraine, which could adversely affect our business in certain regions, the impact of inflation, disruptions in the supply chain, Mannatech's inability to attract and retain associates and preferred customers, increases in competition, litigation, regulatory changes, and its planned growth into new international markets. Although Mannatech believes that the expectations, statements, and assumptions reflected in these forward-looking statements are reasonable, it cautions readers to always consider all of the risk factors and any other cautionary statements carefully in evaluating each forward-looking statement in this release, as well as those set forth in its latest Annual Report on Form 10-K, and other filings filed with the United States Securities and Exchange Commission, including its current reports on Form 8-K. All of the forward-looking statements contained herein speak only as of the date of this release.

    Individuals interested in Mannatech's products or in exploring its business opportunity can learn more at Mannatech.com

     

    MANNATECH, INCORPORATED AND SUBSIDIARIES

    CONSOLIDATED BALANCE SHEETS

    (in thousands, except share information)

     

    ASSETS

    September 30, 2023 (unaudited)

     

    December 31, 2022

    Cash and cash equivalents

    $

    7,928

     

     

    $

    13,777

     

    Restricted cash

     

    938

     

     

     

    944

     

    Accounts receivable, net of allowance of $1,315 and $973 in 2023 and 2022, respectively

     

    149

     

     

     

    218

     

    Income tax receivable

     

    418

     

     

     

    423

     

    Inventories, net

     

    15,332

     

     

     

    14,726

     

    Prepaid expenses and other current assets

     

    2,040

     

     

     

    2,389

     

    Deferred commissions

     

    1,779

     

     

     

    2,476

     

    Total current assets

     

    28,584

     

     

     

    34,953

     

    Property and equipment, net

     

    4,326

     

     

     

    3,759

     

    Long-term restricted cash

     

    821

     

     

     

    476

     

    Other assets

     

    7,277

     

     

     

    8,439

     

    Deferred tax assets, net

     

    1,198

     

     

     

    1,501

     

    Total assets

    $

    42,206

     

     

    $

    49,128

     

    LIABILITIES AND SHAREHOLDERS' EQUITY

     

     

     

    Current portion of finance leases

    $

    272

     

     

    $

    61

     

    Accounts payable

     

    3,879

     

     

     

    4,361

     

    Accrued expenses

     

    7,547

     

     

     

    7,510

     

    Commissions and incentives payable

     

    9,051

     

     

     

    9,256

     

    Taxes payable

     

    1,311

     

     

     

    3,281

     

    Current notes payable

     

    303

     

     

     

    263

     

    Deferred revenue

     

    3,949

     

     

     

    5,106

     

    Total current liabilities

     

    26,312

     

     

     

    29,838

     

    Finance leases, excluding current portion

     

    1,022

     

     

     

    88

     

    Other long-term liabilities

     

    4,172

     

     

     

    5,026

     

    Total liabilities

     

    31,506

     

     

     

    34,952

     

     

     

     

     

    Commitments and contingencies

     

     

     

     

     

     

     

    Shareholders' equity:

     

     

     

    Preferred stock, $0.01 par value, 1,000,000 shares authorized, no shares issued or outstanding

     

    —

     

     

     

    —

     

    Common stock, $0.0001 par value, 99,000,000 shares authorized, 2,742,857 shares issued and 1,860,154 shares outstanding as of September 30, 2023 and 2,742,857 shares issued and 1,858,800 shares outstanding as of December 31, 2022

     

    —

     

     

     

    —

     

    Additional paid-in capital

     

    33,301

     

     

     

    33,377

     

    Retained earnings

     

    455

     

     

     

    1,686

     

    Accumulated other comprehensive (loss)

     

    (2,547

    )

     

     

    (208

    )

    Treasury stock, at average cost, 882,703 shares as of September 30, 2023 and 884,057 shares as of December 31, 2022

     

    (20,509

    )

     

     

    (20,679

    )

    Total shareholders' equity

     

    10,700

     

     

     

    14,176

     

    Total liabilities and shareholders' equity

    $

    42,206

     

     

    $

    49,128

     

     

    MANNATECH, INCORPORATED AND SUBSIDIARIES

    CONSOLIDATED STATEMENTS OF OPERATIONS

    (in thousands, except per share information)

     

     

    Three Months Ended

    September 30,

     

    Nine Months Ended

    September 30,

     

     

    2023

     

     

     

    2022

     

     

     

    2023

     

     

     

    2022

     

    Net sales

    $

    32,553

     

     

    $

    35,513

     

     

    $

    99,261

     

     

    $

    102,873

     

    Cost of sales

     

    6,625

     

     

     

    7,416

     

     

     

    21,042

     

     

     

    22,427

     

    Gross profit

     

    25,928

     

     

     

    28,097

     

     

     

    78,219

     

     

     

    80,446

     

    Operating expenses:

     

     

     

     

     

     

     

    Commissions and incentives

     

    13,178

     

     

     

    14,242

     

     

     

    40,200

     

     

     

    41,487

     

    Selling and administrative expenses

     

    6,946

     

     

     

    6,656

     

     

     

    20,619

     

     

     

    20,479

     

    Depreciation and amortization expense

     

    450

     

     

     

    716

     

     

     

    1,224

     

     

     

    1,349

     

    Other operating costs

     

    5,182

     

     

     

    5,126

     

     

     

    16,245

     

     

     

    14,886

     

    Total operating expenses

     

    25,756

     

     

     

    26,740

     

     

     

    78,288

     

     

     

    78,201

     

    Income (loss) from operations

     

    172

     

     

     

    1,357

     

     

     

    (69

    )

     

     

    2,245

     

    Interest (expense) income, net

     

    (17

    )

     

     

    19

     

     

     

    (3

    )

     

     

    57

     

    Other income, net

     

    320

     

     

     

    287

     

     

     

    803

     

     

     

    288

     

    Income before income taxes

     

    475

     

     

     

    1,663

     

     

     

    731

     

     

     

    2,590

     

    Income tax (provision)

     

    (457

    )

     

     

    (472

    )

     

     

    (1,214

    )

     

     

    (571

    )

    Net income (loss)

    $

    18

     

     

    $

    1,191

     

     

    $

    (483

    )

     

    $

    2,019

     

    Income (loss) per common share:

     

     

     

     

     

     

     

    Basic

    $

    0.01

     

     

    $

    0.62

     

     

    $

    (0.26

    )

     

    $

    1.05

     

    Diluted

    $

    0.01

     

     

    $

    0.61

     

     

    $

    (0.26

    )

     

    $

    1.01

     

    Weighted-average common shares outstanding:

     

     

     

     

     

     

     

    Basic

     

    1,863

     

     

     

    1,906

     

     

     

    1,868

     

     

     

    1,932

     

    Diluted

     

    1,863

     

     

     

    1,949

     

     

     

    1,868

     

     

     

    2,017

     

    Non-GAAP Financial Measures (Sales, Gross Profit and Income from Operations in Constant Dollars)

    To supplement our financial results presented in accordance with generally accepted accounting principles in the United States ("GAAP"), we disclose operating results that have been adjusted to exclude the impact of changes due to the translation of foreign currencies into U.S. dollars, including changes in: Net Sales, Gross Profit, and Income from Operations. We refer to these adjusted financial measures as constant dollar items, which are non-GAAP financial measures. We believe these measures provide investors an additional perspective on trends. To exclude the impact of changes due to the translation of foreign currencies into U.S. dollars, we calculate current year results and prior year results at a constant exchange rate, which is the prior year's rate. Currency impact is determined as the difference between actual growth rates and constant currency growth rates.

    The table below reconciles third quarter 2023 and year-to-date constant dollar net sales, gross profit and income from operations to our GAAP net sales, gross profit and income from operations.

    Three-month period ended

    September 30, 2023

     

    September 30, 2022

     

     

    Constant $ Change

    (in millions, except percentages)

    GAAP

    Measure:

    Total $

     

    Non-GAAP

    Measure:

    Constant $

     

    GAAP

    Measure:

    Total $

     

    Dollar

     

    Percent

    Net sales

    $

    32.6

     

    $

    32.5

     

    $

    35.5

     

    $

    (3.0

    )

     

    (8.5

    )%

    Product

     

    31.0

     

     

    30.9

     

     

    33.6

     

     

    (2.7

    )

     

    (8.0

    )%

    Pack sales and associate fees

     

    1.2

     

     

    1.2

     

     

    1.7

     

     

    (0.5

    )

     

    (29.4

    )%

    Other

     

    0.4

     

     

    0.4

     

     

    0.2

     

     

    0.2

     

     

    100.0

    %

    Gross profit

     

    25.9

     

     

    25.8

     

     

    28.1

     

     

    (2.3

    )

     

    (8.2

    )%

    (Loss) income from operations

     

    0.2

     

     

    0.2

     

     

    1.4

     

     

    (1.2

    )

     

    (85.7

    )%

    Nine-month period ended

    September 30, 2023

     

    September 30, 2022

     

    Constant $ Change

    (in millions, except percentages)

    GAAP

    Measure:

    Total $

     

    Non-GAAP

    Measure:

    Constant $

     

    GAAP

    Measure:

    Total $

     

    Dollar

     

    Percent

    Net sales

    $

    99.3

     

     

    $

    101.7

     

    $

    102.9

     

    $

    (1.2

    )

     

    (1.2

    )%

    Product

     

    93.9

     

     

     

    96.2

     

     

    97.5

     

     

    (1.3

    )

     

    (1.3

    )%

    Pack sales and associate fees

     

    4.7

     

     

     

    4.8

     

     

    4.8

     

     

    —

     

     

    —

    %

    Other

     

    0.7

     

     

     

    0.7

     

     

    0.6

     

     

    0.1

     

     

    16.7

    %

    Gross profit

     

    78.2

     

     

     

    80.1

     

     

    80.4

     

     

    (0.3

    )

     

    (0.4

    )%

    (Loss) income from operations

     

    (0.1

    )

     

     

    0.5

     

     

    2.2

     

     

    (1.7

    )

     

    (77.3

    )%

     

    View source version on businesswire.com: https://www.businesswire.com/news/home/20231107123134/en/

    Get the next $MTEX alert in real time by email

    Chat with this insight

    Save time and jump to the most important pieces.

    Recent Analyst Ratings for
    $MTEX

    DatePrice TargetRatingAnalyst
    More analyst ratings

    $MTEX
    Insider Purchases

    Insider purchases reveal critical bullish sentiment about the company from key stakeholders. See them live in this feed.

    See more
    • Director Rameson Tyler bought $126,232 worth of shares (16,288 units at $7.75), increasing direct ownership by 6% to 299,197 units (SEC Form 4)

      4 - MANNATECH INC (0001056358) (Issuer)

      9/10/24 5:45:00 PM ET
      $MTEX
      Medicinal Chemicals and Botanical Products
      Health Care

    $MTEX
    SEC Filings

    See more
    • Mannatech Incorporated filed SEC Form 8-K: Results of Operations and Financial Condition, Financial Statements and Exhibits

      8-K - MANNATECH INC (0001056358) (Filer)

      5/13/25 5:06:07 PM ET
      $MTEX
      Medicinal Chemicals and Botanical Products
      Health Care
    • SEC Form 10-Q filed by Mannatech Incorporated

      10-Q - MANNATECH INC (0001056358) (Filer)

      5/13/25 4:57:24 PM ET
      $MTEX
      Medicinal Chemicals and Botanical Products
      Health Care
    • SEC Form DEF 14A filed by Mannatech Incorporated

      DEF 14A - MANNATECH INC (0001056358) (Filer)

      4/22/25 5:01:03 PM ET
      $MTEX
      Medicinal Chemicals and Botanical Products
      Health Care

    $MTEX
    Leadership Updates

    Live Leadership Updates

    See more
    • Mannatech Announces Appointment of Robert A. Toth as Vice Chairman of the Board of Directors

      Mannatech, Incorporated (NASDAQ: MTEX) announced that on November 20, 2024, the Board of Directors of Mannatech, Incorporated (the "Board") appointed Robert A. Toth to the Board where he will serve as Vice Chairman of the Board of Mannatech, Incorporated (the "Company") effective December 1, 2024. Mr. Toth will serve as a Class III director of the Board. Mr. Toth previously served on the Company's Board between March 2008 through May 31, 2023. Mr. Toth previously served as the Chairman of the Compensation and Stock Option Plan Committee, served on the Audit Committee, the Nominating/Governance and Compliance Committee, the Science and Marketing Committee, and from August 2014 to March 201

      11/26/24 4:30:00 PM ET
      $MTEX
      Medicinal Chemicals and Botanical Products
      Health Care
    • Mannatech Announces Appointment of James Clavijo as Chief Financial Officer

      Mannatech, Incorporated (NASDAQ: MTEX) announced that the Board of Directors appointed James Clavijo as Chief Financial Officer of Mannatech Incorporated (the "Company") effective July 1, 2024. James Clavijo brings over 25 years of experience in executive, finance, and accounting activities. He has served as CFO for biotech, medical technology, and pharmaceutical companies, including Longeveron (NASDAQ:LVGN), Guided Therapeutics (OTC:GTHP), Aeterna Zentaris (NASDAQ:AEZS), and Tri-source Pharma. Mr. Clavijo has led and advised companies with strategic plans for pharmaceutical commercialization and manufacturing, has negotiated licensing and drug development agreements, and he has advised c

      7/1/24 5:46:00 PM ET
      $AEZS
      $MTEX
      Biotechnology: Pharmaceutical Preparations
      Health Care
      Medicinal Chemicals and Botanical Products
    • Mannatech Announces Retirement of Alfredo Bala and Promotion of Landen Fredrick to President and CEO

      Mannatech, Incorporated (NASDAQ: MTEX) reported that Alfredo (Al) Bala, announced his retirement as the company's CEO effective April 1, 2024. J. Stanley Fredrick, Chairman of the Board of Mannatech, Incorporated stated, "Al will continue to serve the company as an advisor focused on customer acquisition and sales growth. This transition enables Al to work more closely with our associates in the field which has always been his first love. In this new role, Al will also focus on field and leadership development, leveraging his 43 years of experience in direct sales at both the field and corporate level helping to create and develop programs dedicated to growing people and sales." Mr. Fredr

      3/13/24 7:30:00 PM ET
      $MTEX
      Medicinal Chemicals and Botanical Products
      Health Care

    $MTEX
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    See more
    • SEC Form SC 13G filed by Mannatech Incorporated

      SC 13G - MANNATECH INC (0001056358) (Subject)

      11/1/24 11:44:29 AM ET
      $MTEX
      Medicinal Chemicals and Botanical Products
      Health Care
    • SEC Form SC 13G/A filed by Mannatech Incorporated (Amendment)

      SC 13G/A - MANNATECH INC (0001056358) (Subject)

      1/13/23 11:03:46 AM ET
      $MTEX
      Medicinal Chemicals and Botanical Products
      Health Care
    • SEC Form SC 13G/A filed by Mannatech Incorporated (Amendment)

      SC 13G/A - MANNATECH INC (0001056358) (Subject)

      2/7/22 6:32:28 PM ET
      $MTEX
      Medicinal Chemicals and Botanical Products
      Health Care

    $MTEX
    Press Releases

    Fastest customizable press release news feed in the world

    See more
    • Mannatech Premieres Powerful New Documentary on Marathon Legend Steve Edwards

      "The Long Run" showcases a world-record journey powered by Glycan Replenishment Therapy and unmatched determination. Global health and wellness innovator Mannatech is proud to premiere Steve Edwards: The Long Run, an 11-minute short documentary chronicling the unbelievable true story of Steve Edwards—an everyday man turned endurance icon. With over 1,000 official marathons completed in record-setting average times, Edwards' legacy is one of resilience, quiet determination and the pursuit of human potential. The film debuts globally today, May 21, and is followed by an in-depth interview with Steve Edwards himself following the documentary. It is available to watch free at events.mannatech.

      5/21/25 12:16:00 PM ET
      $MTEX
      Medicinal Chemicals and Botanical Products
      Health Care
    • Mannatech Reports Financial Results for First Quarter 2025

      Mannatech, Incorporated (NASDAQ: MTEX), ("Mannatech" or "Company"), global health and wellness company committed to transforming lives to make a better world, today announced financial results for its first quarter of 2025. First Quarter Highlights Net sales for the quarter ended March 31, 2025 were $26.6 million, as compared to $29.4 million for the same period in 2024, a decrease of $2.8 million, or 9.6%. On a Constant dollar basis (see Non-GAAP Measures, below) our net sales decreased $1.6 million, or 5.4%, and unfavorable foreign exchange caused a $1.2 million decrease in GAAP net sales as compared to the same period in 2024. The decline in revenues was principally due to slowing dem

      5/13/25 6:06:00 PM ET
      $MTEX
      Medicinal Chemicals and Botanical Products
      Health Care
    • Mannatech Reports Fourth Quarter 2024 Financial Results

      Mannatech, Incorporated (NASDAQ: MTEX), a global health and wellness company committed to transforming lives to make a better world, today announced financial results for its fourth quarter of 2024. Quarter End Results Fourth quarter net sales for 2024 were $29.0 million, a decrease of $3.7 million, or 11.3%, as compared to $32.7 million in the fourth quarter of 2023. During the fourth quarter, the company's net sales declined 9.2% on a Constant dollar basis (a Non-GAAP financial measure); unfavorable foreign exchange during the fourth quarter caused a decrease of $0.7 million in net sales as compared to the fourth quarter of 2023. Gross profit as a percentage of net sales improved to 80

      3/26/25 6:00:00 AM ET
      $MTEX
      Medicinal Chemicals and Botanical Products
      Health Care

    $MTEX
    Financials

    Live finance-specific insights

    See more
    • Mannatech Reports Financial Results for First Quarter 2025

      Mannatech, Incorporated (NASDAQ: MTEX), ("Mannatech" or "Company"), global health and wellness company committed to transforming lives to make a better world, today announced financial results for its first quarter of 2025. First Quarter Highlights Net sales for the quarter ended March 31, 2025 were $26.6 million, as compared to $29.4 million for the same period in 2024, a decrease of $2.8 million, or 9.6%. On a Constant dollar basis (see Non-GAAP Measures, below) our net sales decreased $1.6 million, or 5.4%, and unfavorable foreign exchange caused a $1.2 million decrease in GAAP net sales as compared to the same period in 2024. The decline in revenues was principally due to slowing dem

      5/13/25 6:06:00 PM ET
      $MTEX
      Medicinal Chemicals and Botanical Products
      Health Care
    • Mannatech Reports Financial Results for Third Quarter 2024

      Mannatech, Incorporated (NASDAQ: MTEX), ("Mannatech" or "Company"), global health and wellness company committed to transforming lives to make a better world, today announced financial results for its third quarter of 2024. Third Quarter Highlights Net sales for the quarter ended September 30, 2024 were $31.7 million, as compared to $32.6 million for the same period in 2023, a decrease of $0.9 million, or 2.5%. On a Constant dollar basis (see Non-GAAP Measures, below) our net sales decreased $0.4 million, or 1.2%, and unfavorable foreign exchange caused a $0.5 million decrease in GAAP net sales as compared to the same period in 2023. The decline in revenues was principally due to slowi

      11/12/24 4:48:00 PM ET
      $MTEX
      Medicinal Chemicals and Botanical Products
      Health Care
    • Mannatech Reports Financial Results for Second Quarter 2024

      Mannatech, Incorporated (NASDAQ: MTEX), ("Mannatech" or "Company"), global health and wellness company committed to transforming lives to make a better world, today announced financial results for its second quarter of 2024. Second Quarter Highlights Net sales for the quarter ended June 30, 2024 were $27.7 million, as compared to $32.6 million for the same period in 2023, a decrease of $4.9 million, or 14.9%. On a Constant dollar basis (see Non-GAAP Measures, below) our net sales decreased $4.2 million, or 12.9%, and unfavorable foreign exchange caused a $0.7 million decrease in GAAP net sales as compared to the same period in 2023. The decline in revenues was principally due to supply

      8/13/24 5:00:00 PM ET
      $MTEX
      Medicinal Chemicals and Botanical Products
      Health Care

    $MTEX
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    See more
    • Amendment: SEC Form 4 filed by Director Toth Robert

      4/A - MANNATECH INC (0001056358) (Issuer)

      3/17/25 1:23:48 PM ET
      $MTEX
      Medicinal Chemicals and Botanical Products
      Health Care
    • Director Fredrick J Stanley was granted 2,686 units of Common Stock Par Value $0.0001 Per Share, increasing direct ownership by 0.76% to 356,975 units (SEC Form 4)

      4 - MANNATECH INC (0001056358) (Issuer)

      1/6/25 12:37:18 PM ET
      $MTEX
      Medicinal Chemicals and Botanical Products
      Health Care
    • Director Toth Robert was granted 2,686 units of Common Stock Par Value $0.0001 Per Share, increasing direct ownership by 3% to 91,130 units (SEC Form 4)

      4 - MANNATECH INC (0001056358) (Issuer)

      1/6/25 12:37:07 PM ET
      $MTEX
      Medicinal Chemicals and Botanical Products
      Health Care